Engineering effective T-cell based antitumor immunity

The adoptive transfer of synthetic siRNA-mediated cblb-depleted autologous CD8(+) T cells acts as a potent adjuvant for dendritic cell (DC) vaccination and provides a significant therapeutic benefit. Our proof-of-concept study validates the strategy of inhibiting CBLB as a rational approach to augme...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruber, Thomas, Hinterleitner, Reinhard, Pfeifhofer-Obermair, Christa, Wolf, Dominik, Baier, Gottfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601162/
https://www.ncbi.nlm.nih.gov/pubmed/23525844
http://dx.doi.org/10.4161/onci.22893
_version_ 1782475727613984768
author Gruber, Thomas
Hinterleitner, Reinhard
Pfeifhofer-Obermair, Christa
Wolf, Dominik
Baier, Gottfried
author_facet Gruber, Thomas
Hinterleitner, Reinhard
Pfeifhofer-Obermair, Christa
Wolf, Dominik
Baier, Gottfried
author_sort Gruber, Thomas
collection PubMed
description The adoptive transfer of synthetic siRNA-mediated cblb-depleted autologous CD8(+) T cells acts as a potent adjuvant for dendritic cell (DC) vaccination and provides a significant therapeutic benefit. Our proof-of-concept study validates the strategy of inhibiting CBLB as a rational approach to augment the effectiveness of adoptively transferred immune cells.
format Online
Article
Text
id pubmed-3601162
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36011622013-03-22 Engineering effective T-cell based antitumor immunity Gruber, Thomas Hinterleitner, Reinhard Pfeifhofer-Obermair, Christa Wolf, Dominik Baier, Gottfried Oncoimmunology Author's View The adoptive transfer of synthetic siRNA-mediated cblb-depleted autologous CD8(+) T cells acts as a potent adjuvant for dendritic cell (DC) vaccination and provides a significant therapeutic benefit. Our proof-of-concept study validates the strategy of inhibiting CBLB as a rational approach to augment the effectiveness of adoptively transferred immune cells. Landes Bioscience 2013-02-01 /pmc/articles/PMC3601162/ /pubmed/23525844 http://dx.doi.org/10.4161/onci.22893 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Gruber, Thomas
Hinterleitner, Reinhard
Pfeifhofer-Obermair, Christa
Wolf, Dominik
Baier, Gottfried
Engineering effective T-cell based antitumor immunity
title Engineering effective T-cell based antitumor immunity
title_full Engineering effective T-cell based antitumor immunity
title_fullStr Engineering effective T-cell based antitumor immunity
title_full_unstemmed Engineering effective T-cell based antitumor immunity
title_short Engineering effective T-cell based antitumor immunity
title_sort engineering effective t-cell based antitumor immunity
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601162/
https://www.ncbi.nlm.nih.gov/pubmed/23525844
http://dx.doi.org/10.4161/onci.22893
work_keys_str_mv AT gruberthomas engineeringeffectivetcellbasedantitumorimmunity
AT hinterleitnerreinhard engineeringeffectivetcellbasedantitumorimmunity
AT pfeifhoferobermairchrista engineeringeffectivetcellbasedantitumorimmunity
AT wolfdominik engineeringeffectivetcellbasedantitumorimmunity
AT baiergottfried engineeringeffectivetcellbasedantitumorimmunity

Ejemplares similares